Positive Phase II Study of Pacira's EXPAREL(TM) (DepoBupivacaine) in Hernia Repair Presented at the Postgraduate Assembly in Anesthesio...(ology owned byPacira. Two other DepoFoa...),Health

Date:12/14/2008

ology owned by Pacira. Two other DepoFoam-based products -- DepoDur(R) and DepoCyt/DepoCyte(R) -- are marketed by partners in several global territories. The DepoFoam technology also forms the basis of multiple development projects providing Pacira an opportunity to expand its pipeline. Pacira owns two cGMP production facilities which produce the two approved products, EXPAREL clinical development and all pipeline materials.

Additional information about Pacira is available at www.pacira.com.

This news release and the anticipated presentation contain forward-looking statements that involve risks and uncertainties, including statements relating to initiation and progress of the Company's clinical trial programs and the preliminary results from the clinical trials. Actual results could differ materially from those projected and the Company cautions readers not to place undue reliance on the forward-looking statements contained in the release and anticipated presentation.

Editor's Notes:

-- "A single administration of DepoBupivacaine(TM) intraoperative results in prolonged detectable plasma bupivacaine and analgesia in patients undergoing inguinal hernia repair" by Richard M. Langford, FRCA; G.M Chappell, FRACS; Jeff A. Karrasch, FRACP, poster presented December 14, 2008 at the PostGraduate Assembly in Anesthesiology (PGA) of the New York State Society of Anesthesiologists, is available at www.pacira.com

-- Pacira Pharmaceuticals executives are available for interviews upon request.

CONTACT: Taunia Markvicka, 973-254-3565.

'/>"/>

SOURCE Pacira Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH
2. Positive Phase 1 Clinical Trial Results for Transdermal Lidocaine
3. Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
4. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for the Management of Fibromyalgia
5. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress
6. Kiadis Pharma Announces Positive Clinical Results for ATIR(TM) in Mismatched Bone Marrow Transplantations
7. Third Pivotal Phase 3 Study for NicOx Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results
8. Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union
9. Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia
10. Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
11. Vical Completes Enrollment and Reports Positive Interim Data in CMV Vaccine Phase 2 Trial